Proficio Capital Partners LLC Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Proficio Capital Partners LLC raised its position in Moderna, Inc. (NASDAQ:MRNA) by 4,418.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 147,360 shares of the company’s stock after purchasing an additional 144,099 shares during the quarter. Proficio Capital Partners LLC’s holdings in Moderna were worth $6,127,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Banco Santander S.A. purchased a new position in shares of Moderna in the third quarter valued at about $3,550,000. John G Ullman & Associates Inc. increased its position in shares of Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after acquiring an additional 38,400 shares during the period. abrdn plc increased its position in shares of Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares during the period. Y Intercept Hong Kong Ltd increased its position in shares of Moderna by 30.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock valued at $6,760,000 after acquiring an additional 23,881 shares during the period. Finally, Spire Wealth Management increased its position in shares of Moderna by 2,150.4% in the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock valued at $966,000 after acquiring an additional 22,192 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the topic of several research analyst reports. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Citigroup initiated coverage on shares of Moderna in a research report on Thursday. They set a “neutral” rating and a $40.00 price target on the stock. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Finally, Bank of America reduced their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $59.60.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $34.62 on Monday. The firm’s 50 day moving average price is $35.94 and its 200-day moving average price is $47.15. The company has a market cap of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.